ROZLYTREK (entrectinib) Mechanism of Action | HCP
Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases | SpringerLink
ROS1-dependent cancers — biology, diagnostics and therapeutics | Nature Reviews Clinical Oncology
Cancers | Free Full-Text | Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies | HTML
Frontiers | The Evolving Role of Radiotherapy for Pediatric Cancers With Advancements in Molecular Tumor Characterization and Targeted Therapies | Oncology
Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer - Katayama - 2018 - Cancer Science - Wiley Online Library
Frontiers | NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK Inhibitor Resistance | Oncology
From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer | Nature Reviews Clinical Oncology
Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme - ScienceDirect
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types - ScienceDirect
ROZLYTREK (entrectinib) Efficacy | NTRK Fusion+ Solid Tumors
Entrectinib治疗携带NTRK1/2/3、ROS1和ALK基因变异的儿科实体肿瘤，效果确切
New Targets in Non–Small Cell Lung Cancer | Oncohema Key
Frontiers | Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer | Medicine
Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases | SpringerLink
TRK inhibitors block NFKB and induce NRF2 in TRK fusion-positive colon cancer
Profile of entrectinib and its potential in the treatment of ROS1-posi | LCTT
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer - ScienceDirect
Entrectinib - Wikipedia
Prioritizing the Catalytic Gatekeepers through Pan- Inhibitory Mechanism of Entrectinib against ALK, ROS1 and TRKA Tyrosine Kinases | SpringerLink
Evolving role of entrectinib in treatment of NTRK-positive tumors | Future Oncology
Rozlytrek (entrectinib) for the Treatment of Solid Tumours, Japan
Frontiers | NTRK Fusions and TRK Inhibitors: Potential Targeted Therapies for Adult Glioblastoma | Oncology
